Lumos Pharma, Inc. (LUMO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Austin, TX, 미국. 현재 CEO는 Richard J. Hawkins.
LUMO 을(를) 보유 IPO 날짜 2011-11-11, 30 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $37.54M.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
